Management of Extraglandular Manifestations of Primary Sjogren's Syndrome

被引:5
作者
Wu, Jason J. [1 ,2 ]
Carsons, Steven E. [1 ,3 ]
机构
[1] Winthrop Univ Hosp, Dept Med, Div Rheumatol Allergy & Immunol, Mineola, NY 11501 USA
[2] Nassau Cty Med Ctr, E Meadow, NY 11554 USA
[3] SUNY Stony Brook, Sch Med, Stony Brook, NY 11794 USA
关键词
Sjogren's syndrome; Joint pain; NSAIDs; Anti-TNF; POLYUNSATURATED FATTY-ACIDS; DOUBLE-BLIND; CLINICAL-SIGNIFICANCE; RHEUMATOID-ARTHRITIS; FATIGUE; INVOLVEMENT; RITUXIMAB; VASCULITIS; EFFICACY;
D O I
10.1016/j.coms.2013.09.009
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Primary Sjogren's syndrome can have multiple extra-glandular manifestations ranging from mild to severe. Treatment for extra-glandular manifestations is organ specific and therapies are targeted based on the primary organs involved. Preferred treatment options used for extra-glandular manifestations of Sjogren's syndrome are usually extrapolated from the physician's experience in treating similar manifestations in other autoimmune conditions such as rheumatoid arthritis and systemic lupus erythematous. The lack of immunomodulating disease modifying drugs in Sjogren's syndrome can be frustrating for patients dealing with extra-glandular manifestations, however recent advances in the field has made the future look promising for new therapeutic options.
引用
收藏
页码:101 / +
页数:10
相关论文
共 44 条
[1]   White matter abnormalities in primary Sjogren syndrome [J].
Akasbi, M. ;
Berenguer, J. ;
Saiz, A. ;
Brito-Zeron, P. ;
Perez-De-Lis, M. ;
Bove, A. ;
Diaz-Lagares, C. ;
Retamozo, S. ;
Blanco, Y. ;
Perez-Alvarez, R. ;
Bosch, X. ;
Siso, A. ;
Graus, F. ;
Ramos-Casals, M. .
QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2012, 105 (05) :433-443
[2]   Peripheral Nervous System Manifestations of Sjogren Syndrome Clinical Patterns, Diagnostic Paradigms, Etiopathogenesis, and Therapeutic Strategies [J].
Birnbaum, Julius .
NEUROLOGIST, 2010, 16 (05) :287-297
[3]  
Botez Stephan A, 2010, J Clin Neuromuscul Dis, V11, P127, DOI 10.1097/CND.0b013e3181c50513
[4]  
Bourcier Matthew E, 2008, Ther Clin Risk Manag, V4, P837
[5]   Omega-3 polyunsaturated fatty acids and inflammatory processes: nutrition or pharmacology? [J].
Calder, Philip C. .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 75 (03) :645-662
[6]  
Chen L, 2012, SJOGRENS BOOK, P235
[7]   Rituximab treatment for Sjogren syndrome-associated non-Hodgkin's lymphoma: case series [J].
Covelli, M. ;
Lanciano, E. ;
Tartaglia, P. ;
Grattagliano, V. ;
Angelelli, G. ;
Atzeni, F. ;
Sarzi-Puttini, P. ;
Lapadula, G. .
RHEUMATOLOGY INTERNATIONAL, 2012, 32 (10) :3281-3284
[8]   Reduction of fatigue in Sjogren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study [J].
Dass, S. ;
Bowman, S. J. ;
Vital, E. M. ;
Ikeda, K. ;
Pease, C. T. ;
Hamburger, J. ;
Richards, A. ;
Rauz, S. ;
Emery, P. .
ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (11) :1541-1544
[9]  
Durez P, 1998, J RHEUMATOL, V25, P1032
[10]   Articular manifestations in primary Sjogren's syndrome: clinical significance and prognosis of 188 patients [J].
Fauchais, Anne-Laure ;
Ouattara, Bali ;
Gondran, Guillaume ;
Lalloue, Fabrice ;
Petit, Daniel ;
Ly, Kim ;
Lambert, Marc ;
Launay, David ;
Loustaud-Ratti, Veronique ;
Bezanahari, Holly ;
Liozon, Eric ;
Hachulla, Eric ;
Jauberteau, Marie-Odile ;
Vidal, Elisabeth ;
Hatron, Pierre-Yves .
RHEUMATOLOGY, 2010, 49 (06) :1164-1172